Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
Vaccine
; 40(50): 7187-7190, 2022 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2132600
ABSTRACT
In 2018, CDC recommended a highly efficacious adjuvanted recombinant zoster vaccine (RZV) as a 2-dose series for prevention of herpes zoster (HZ) for immunocompetent persons age ≥ 50 years, with the 2nd dose recommended 2-6 months after the 1st dose. We estimated second-dose RZV series completion in the U.S. among 50-64-year-olds using two administrative databases. Second-dose RZV series completion was â¼70% within 6-months and 80% within 12-months of first dose. Among those who received only 1 RZV dose with at least 12 months of follow-up time, 96% had a missed opportunity for a second-dose vaccination, defined as a provider or pharmacy visit, among whom 36% had a visit for influenza or pneumococcal vaccination within 2-12 months of their first-dose of RZV. We found that RZV series completion rates in 50-64-year-olds was high. Availability of RZV at pharmacies has potentially helped increase series completion, but missed opportunities remain.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Gripe Humana
/
Vacuna contra el Herpes Zóster
/
Herpes Zóster
Tipo de estudio:
Estudio de cohorte
/
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Adulto
/
Humanos
País/Región como asunto:
America del Norte
Idioma:
Inglés
Revista:
Vaccine
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS